Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Chronic Heart Failure

Current Evidence, Challenges to Therapy, and Future Directions

  • 543 Accesses

  • 29 Citations

Abstract

Heart failure (HF) is a complex syndrome characterized by the inability of the heart to maintain a normal cardiac output without elevated intracardiac filling pressures, resulting in signs of pulmonary and peripheral edema and symptoms of dyspnea and fatigue. Central to the management of HF is a multifaceted pharmacological intervention to abate the harmful counter-regulatory effects of neurohormonal activation and avid salt and water retention. Whereas up to 40 years ago HF was managed with diuretics and leaf of digitalis, the cornerstones of therapy for HF patients with systolic dysfunction now include ACE inhibitors or angiotensin II type 1 receptor antagonists (angiotensin receptor blockers), β-adrenoceptor antagonists (β-blockers), and aldosterone antagonists, which have significantly improved survival. However, with the increasing number of beneficial therapies, there are challenges to implementing all of them. Specific cardiomyopathies also merit specific considerations with respect to treatment, and — unfortunately — there is no therapy for HF with preserved left ventricular ejection fraction that has been shown to improve survival. Although mortality has improved in HF, the biggest challenge to treatment lies in addressing the morbidity of this disease, which is now the most common reason for hospital admission in our aged population. As such, there are many therapies that may serve to improve the quality of life of HF patients. Future HF treatment regimens may include direct cellular therapy via hormone and cytokine signaling or cardiac regeneration through growth factors or cell therapy.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Lindenfeld J, Albert NM, Boehmer JP, et al. HFSA 2010 comprehensive heart failure practice guideline. J Card Fail 2010; 16: e1–194.

  2. 2.

    Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics — 2010 update: a report from the American Heart Association. Circulation 2010; 121: e46–215.

  3. 3.

    Jessup M, Abraham WT, Casey DE, et al. 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119: 1977–2016.

  4. 4.

    Nanthakumar K, Epstein AE, Kay GN, et al. Prophylactic implantable cardioverter-defibrillator therapy in patients with left ventricular systolic dysfunction: a pooled analysis of 10 primary prevention trials. J Am Coll Cardiol 2004; 44: 2166–72.

  5. 5.

    Turley AJ, Raja SG, Salhiyyah K, et al. Does cardiac resynchronisation therapy improve survival and quality of life in patients with end-stage heart failure? Interact Cardio Vasc Thorac Surg 2008; 7: 1141–6.

  6. 6.

    Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term use of a left ventricular assist device for end-stage heart failure. New Engl J Med 2001; 345: 1435–43.

  7. 7.

    Slaughter MS, Rogers JG, Milano CA, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. New Engl J Med 2009; 361: 2241–51.

  8. 8.

    Koch-Weser J, Cohn JN, Franciosa JA. Vasodilator therapy of cardiac failure. New Engl J Med 1977; 297: 27–31.

  9. 9.

    Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. New Engl J Med 1986; 314: 1547–52.

  10. 10.

    A placebo-controlled trial of captopril in refractory chronic congestive heart failure. J Am Coll Cardiol 1983; 2: 755–63.

  11. 11.

    The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. New Engl J Med 1987; 316: 1429–35.

  12. 12.

    The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. New Engl J Med 1991; 325: 293–302.

  13. 13.

    The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. New Engl J Med 1992; 327: 685–91.

  14. 14.

    Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. New Engl J Med 1992; 327: 669–77.

  15. 15.

    Swedberg K, Held P, Kjekshus J, et al. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. New Engl J Med 1992; 327: 678–84.

  16. 16.

    Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. New Engl J Med 1991; 325: 303–10.

  17. 17.

    Fonarow GC, Chelimsky-Fallick C, Stevenson LW, et al. Effect of direct vasodilation with hydralazine versus angiotensin-converting enzyme inhibition with captopril on mortality in advanced heart failure: the Hy-C trial. J Am Coll Cardiol 1992; 19: 842–50.

  18. 18.

    Ainscough JF, Drinkhill MJ, Sedo A, et al. Angiotensin II type-1 receptor activation in the adult heart causes blood pressure-independent hypertrophy and cardiac dysfunction. Cardiovasc Res 2009; 81: 592–600.

  19. 19.

    Qi G, Jia L, Li Y, et al. Angiotensin II infusion-induced inflammation, monocytic fibroblast precursor infiltration, and cardiac fibrosis are pressure dependent. Cardiovasc Toxicol 2011: 1–11.

  20. 20.

    Gurantz D, Cowling RT, Varki N, et al. IL-1beta and TNF-alpha upregulate angiotensin II type 1 (AT1) receptors on cardiac fibroblasts and are associated with increased AT1 density in the post-MI heart. J Mol Cell Cardiol 2005; 38: 505–15.

  21. 21.

    Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011; 342: c7086.

  22. 22.

    Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 1999; 100: 2312–8.

  23. 23.

    Gullestad L, Aukrust Pa, Ueland T, et al. Effect of high- versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure. J Am Coll Cardiol 1999; 34: 2061–7.

  24. 24.

    Roffman DS. High- versus low-dose ACE inhibitor therapy in chronic heart failure. Ann Pharmacother 2004; 38: 831–8.

  25. 25.

    Frances CD, Noguchi H, Massie BM, et al. Are we inhibited? Renal insufficiency should not preclude the use of ace inhibitors for patients with myocardial infarction and depressed left ventricular function. Arch Intern Med 2000; 160: 2645–50.

  26. 26.

    Dicpinigaitis PV. Angiotensin-converting enzyme inhibitor-induced cough. Chest 2006; 129: 169S–73S.

  27. 27.

    Hartman JC. The role of bradykinin and nitric oxide in the cardioprotective action of ACE inhibitors. Ann Thorac Surg 1995; 60: 789–92.

  28. 28.

    Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial. The Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582–7.

  29. 29.

    Kenneth D, John K. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet 2002; 360: 752–60.

  30. 30.

    Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362: 759–66.

  31. 31.

    Granger CB, McMurray JJV, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362: 772–6.

  32. 32.

    McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362: 767–71.

  33. 33.

    Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362: 777–81.

  34. 34.

    Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. New Engl J Med 2001; 345: 1667–75.

  35. 35.

    Pfeffer MA, McMurray JJV, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. New Engl J Med 2003; 349: 1893–906.

  36. 36.

    Phillips CO, Kashani A, Ko DK, et al. Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials. Arch Intern Med 2007; 167: 1930–6.

  37. 37.

    Lakhdar R, Al-Mallah MH, Lanfear DE. Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta-analysis of randomized controlled trials. J Card Fail 2008; 14: 181–8.

  38. 38.

    Maggioni AP, Anand I, Gottlieb SO, et al. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 2002; 40: 1414–21.

  39. 39.

    Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547–59.

  40. 40.

    Kuenzli A, Bucher HC, Anand I, et al. Meta-analysis of combined therapy with angiotensin receptor antagonists versus ACE inhibitors alone in patients with heart failure. PLoS One 2010; 5: e9946.

  41. 41.

    McMurray JJV, Pitt B, Latini R, et al. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 2008; 1: 17–24.

  42. 42.

    Waagstein F, Hjalmarson A, Varnauskas E, et al. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 1975; 37: 1022–36.

  43. 43.

    CIBIS Investigators and Committees. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994; 90: 1765–73.

  44. 44.

    Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet 1993; 342: 1441–6.

  45. 45.

    Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334: 1349–55.

  46. 46.

    Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: The Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). JAMA 2000; 283: 1295–302.

  47. 47.

    The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II). A randomised trial. Lancet 1999; 353: 9–13.

  48. 48.

    Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002; 106: 2194–9.

  49. 49.

    Toprol-XL: Highlights of prescribing information. AstraZeneca, 2010.

  50. 50.

    Kukin ML, Mannino MM, Freudenberger RS, et al. Hemodynamic comparison of twice daily metoprolol tartrate with once daily metoprolol succinate in congestive heart failure. J Am Coll Cardiol 2000; 35: 45–50.

  51. 51.

    Brophy JM, Joseph L, Rouleau JL. β-Blockers in congestive heart failure: a Bayesian meta-analysis. Ann Internal Med 2001; 134: 550–60.

  52. 52.

    Jabbour A, Macdonald PS, Keogh AM, et al. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. J Am Coll Cardiol 2000; 55: 1780–7.

  53. 53.

    McAlister FA, Wiebe N, Ezekowitz JA, et al. Meta-analysis: β-Blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med 2009; 150: 784–94.

  54. 54.

    Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995; 273: 1450–6.

  55. 55.

    Komajda M, Lutiger B, Madeira H, et al. Tolerability of carvedilol and ACE-inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN). Eur J Heart Fail 2004; 6: 467–75.

  56. 56.

    Willenheimer R. How to begin treatment in chronic heart failure? Results of CIBIS III. Eur Heart J Suppl. 2006; 8: C43–50.

  57. 57.

    Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. New Engl J Med 1999; 341: 709–17.

  58. 58.

    Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. New Engl J Med 2003; 348: 1309–21.

  59. 59.

    Zannad F, McMurray JJV, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. New Engl J Med 2011; 364: 11–21.

  60. 60.

    Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the randomized aldactone evaluation study. New Engl J Med 2004; 351: 543–51.

  61. 61.

    Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004; 351: 2049–57.

  62. 62.

    Cohn JN, Ziesche S, Smith R. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril. Circulation 1997; 96: 856–63.

  63. 63.

    Packer M, O’Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med 1996; 335: 1107–14.

  64. 64.

    Elkayam U, Amin J, Mehra A, et al. A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedi-pine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure. Circulation 1990; 82: 1954–61.

  65. 65.

    Klugmann S, Salvi A, Camerini F. Haemodynamic effects of nifedipine in heart failure. Br Heart J 1980; 43: 440–6.

  66. 66.

    Jentzer JC, DeWald TA, Hernandez AF. Combination of loop diuretics with thiazide-type diuretics in heart failure. J Am Coll Cardiol 2010; 56: 1527–34.

  67. 67.

    Brater DC, Fox WR, Chennavasin P. Electrolyte excretion patterns: intravenous and oral doses of bumetanide compared to furosemide. J Clin Pharmacol 1981; 21: 599–603.

  68. 68.

    Brater DC, Day B, Burdette A, et al. Bumetanide and furosemide in heart failure. Kidney Int 1984; 26: 183–9.

  69. 69.

    Murray MD, Deer MM, Ferguson JA, et al. Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure. Am J Med 2001; 111: 513–20.

  70. 70.

    Stroupe KT, Forthofer MM, Brater DC, et al. Healthcare costs of patients with heart failure treated with torasemide or furosemide. Pharmacoeconomics 2000; 17: 429–40.

  71. 71.

    Muller K, Gamba G, Jaquet F, et al. Torsemide vs. furosemide in primary care patients with chronic heart failure NYHA II to IV: efficacy and quality of life. Eurn J Heart Fail 2003; 5: 793–801.

  72. 72.

    Sheppard R, Panyon J, Pohwani AL, et al. Intermittent outpatient ultra-filtration for the treatment of severe refractory congestive heart failure. J Card Fail 2004; 10: 380–3.

  73. 73.

    Scott RL. Clinical efficacy of intermittent outpatient ultrafiltration in refractory heart failure: a novel approach to heart failure management. International Society for Heart and Lung Transplantation 2009 Scientific Sessions. Paris: 2009.

  74. 74.

    Costanzo MR, Saltzberg MT, Jessup M, et al. Ultrafiltration is associated with fewer rehospitalizations than continuous diuretic infusion in patients with decompensated heart failure: results from UNLOAD. J Card Fail 2010; 16: 277–84.

  75. 75.

    Wilkins MR, Kendall MJ, Wade OL. William Withering and digitalis, 1785 to 1985. Br Med J (Clin Res Ed) 1985; 290: 7–8.

  76. 76.

    Smith TW. Digoxin in heart failure. New Engl J Med 1993; 329: 51–3.

  77. 77.

    The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336: 525–33.

  78. 78.

    Uretsky BF, Young JB, Shahidi FE, et al. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. PROVED Investigative Group. J Am Coll Cardiol 1993; 22: 955–62.

  79. 79.

    Packer M, Gheorghiade M, Young JB, et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study. N Engl J Med 1993; 329: 1–7.

  80. 80.

    Hood Jr WB, Dans AL, Guyatt GH, et al. Digitalis for treatment of congestive heart failure in patients in sinus rhythm. Cochrane Database Syst Rev 2004; CD002901.

  81. 81.

    Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 2002; 347: 1403–11.

  82. 82.

    Hershberger RE, Nauman D, Walker TL, et al. Care processes and clinical outcomes of continuous outpatient support with inotropes (COSI) in patients with refractory endstage heart failure. J Card Fail 2003; 9: 180–7.

  83. 83.

    Gorodeski EZ, Chu EC, Reese JR, et al. Prognosis on chronic dobutamine or milrinone infusions for stage d heart failure. Circ Heart Fail 2009; 2: 320–4.

  84. 84.

    Felker GM, O’Connor CM. Inotropic therapy for heart failure: an evidence-based approach. Am Heart J 2001; 142: 393–401.

  85. 85.

    Parissis JT, Andreadou I, Bistola V, et al. Novel biologic mechanisms of levosimendan and its effect on the failing heart. Expert Opin Investig Drugs 2008; 17: 1143–50.

  86. 86.

    Follath F, Cleland JG, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002; 360: 196–202.

  87. 87.

    Mebazaa A, Nieminen MS, Packer M, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA 2007; 297: 1883–91.

  88. 88.

    DiBianco R, Shabetai R, Silverman BD, et al. Oral amrinone for the treatment of chronic congestive heart failure: results of a multicenter randomized double-blind and placebo-controlled withdrawal study. J Am Coll Cardiol 1984; 4: 855–66.

  89. 89.

    Lowes BD, Shakar SF, Metra M, et al. Rationale and design of the enoximone clinical trials program. J Card Fail 2005; 11: 659–69.

  90. 90.

    Feldman AM, Oren RM, Abraham WT, et al. Low-dose oral enoximone enhances the ability to wean patients with ultra-advanced heart failure from intravenous inotropic support: results of the oral enoximone in intravenous inotrope-dependent subjects trial. Am Heart J 2007; 154: 861–9.

  91. 91.

    Metra M, Eichhorn E, Abraham WT, et al. Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials. Eur Heart J 2009; 30: 3015–26.

  92. 92.

    Nieminen MS, Cleland JG, Eha J, et al. Oral levosimendan in patients with severe chronic heart failure. The PERSIST study. Eur J Heart Fail 2008; 10: 1246–54.

  93. 93.

    Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure. Circulation 2003; 107: 223–5.

  94. 94.

    Horwich TB, Fonarow GC, Hamilton MA, et al. Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol 2002; 39: 1780–6.

  95. 95.

    Ghali JK, Anand IS, Abraham WT, et al. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Circulation 2008; 117: 526–35.

  96. 96.

    RED-HF™ Trial — Reduction of Events with Darbepoetin Alfa in Heart Failure Ttrial [online]. Available from URL: http://clinicaltrials.gov/ct2/show/NCT00358215 [Accessed 2011 May 2].

  97. 97.

    Jankowska EA, Rozentryt P, Witkowska A, et al. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J 2010 Aug; 31(15): 1872–80.

  98. 98.

    Epstein FH, Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med 2001; 344: 501–9.

  99. 99.

    Gerdes AM, Iervasi G. Thyroid replacement therapy and heart failure. Circulation 2010; 122: 385–93.

  100. 100.

    Pingitore A, Galli E, Barison A, et al. Acute effects of triiodothyronine (T3) replacement therapy in patients with chronic heart failure and low-T3 syndrome: a randomized, placebo-controlled study. J Clin Endocrinol Metab 2008; 93: 1351–8.

  101. 101.

    Goldman S, McCarren M, Morkin E, et al. DITPA (3,5-diiodothyr-opropionic acid), a thyroid hormone analog to treat heart failure: Phase II Trial Veterans Affairs Cooperative Study. Circulation 2009; 119: 3093–100.

  102. 102.

    Agarwal M, Naghi J, Philip K, et al. Growth hormone and testosterone in heart failure therapy. Expert Opin Pharmacother 2010; 11: 1835–44.

  103. 103.

    Watanabe S, Tamura T, Ono K, et al. Insulin-like growth factor axis (insulin-like growth factor-I/insulin-like growth factor-binding protein-3) as a prognostic predictor of heart failure: association with adiponectin. Eur J Heart Fail 2010; 12: 1214–22.

  104. 104.

    Cittadini A, Saldamarco L, Marra AM, et al. Growth hormone deficiency in patients with chronic heart failure and beneficial effects of its correction. J Clin Endocrinol Metab 2009; 94: 3329–36.

  105. 105.

    Pugh PJ, Jones RD, West JN, et al. Testosterone treatment for men with chronic heart failure. Heart 2004; 90: 446–7.

  106. 106.

    Malkin CJ, Pugh PJ, West JN, et al. Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. Eur Heart J 2006; 27: 57–64.

  107. 107.

    Iellamo F, Volterrani M, Caminiti G, et al. Testosterone therapy in women with chronic heart failure: a pilot double-blind, randomized, placebo-controlled study. J Am Coll Cardiol 2010; 56: 1310–6.

  108. 108.

    Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N Engl J Med 2010; 363: 109–22.

  109. 109.

    Finley IV JJ, Konstam MA, Udelson JE, et al. Arginine vasopressin antagonists for the treatment of heart failure and hyponatremia. Circulation 2008; 118: 410–21.

  110. 110.

    Gheorghiade M, Gattis WA, O’Connor CM, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 2004; 291: 1963–71.

  111. 111.

    Konstam MA, Gheorghiade M, Burnett Jr JC, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007; 297: 1319–31.

  112. 112.

    Udelson JE, Smith WB, Hendrix GH, et al. Acute hemodynamic effects of conivaptan, a dual V1A and V2 vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 2001; 104: 2417–23.

  113. 113.

    Gheorghiade M, Niazi I, Ouyang J, et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation 2003; 107: 2690–6.

  114. 114.

    Udelson JE, McGrew FA, Flores E, et al. Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction. J Am Coll Cardiol 2007; 49: 2151–9.

  115. 115.

    Abraham WT, Aranda JM, Boehmer JP, et al. Rationale and design of the treatment of hyponatremia based on lixivaptan in NYHA class III/IV cardiac patient evaluation (THE BALANCE) study. Clin Transl Sci 2010; 3: 249–53.

  116. 116.

    Domian IJ, Buikema JW, de Boer RA, et al. Stem cells in heart failure. Eur J Heart Fail 2010; 12: 642–4.

  117. 117.

    Strauer BE, Yousef M, Schannwell CM. The acute and long-term effects of intracoronary Stem cell Transplantation in 191 patients with chronic heARt failure: the STAR-heart study. Eur J Heart Fail 2010; 12: 721–9.

  118. 118.

    Beohar N, Rapp J, Pandya S, et al. Rebuilding the damaged heart: the potential of cytokines and growth factors in the treatment of ischemic heart disease. J Am Coll Cardiol 2010; 56: 1287–97.

  119. 119.

    Ly H, Kawase Y, Yoneyama R, et al. Gene therapy in the treatment of heart failure. Physiology (Bethesda) 2007; 22: 81–96.

  120. 120.

    Kawase Y, Ly HQ, Prunier F, et al. Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure. J Am Coll Cardiol 2008; 51: 1112–9.

  121. 121.

    Jaski BE, Jessup ML, Mancini DM, et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID trial), a first-in-human phase 1/2 clinical trial. J Card Fail 2009; 15: 171–81.

  122. 122.

    Bock-Marquette I, Shrivastava S, Pipes GC, et al. Thymosin beta4 mediated PKC activation is essential to initiate the embryonic coronary developmental program and epicardial progenitor cell activation in adult mice in vivo. J Mol Cell Cardiol 2009; 46: 728–38.

  123. 123.

    Bock-Marquette I, Saxena A, White MD, et al. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature 2004; 432: 466–72.

  124. 124.

    Movsesian M, Stehlik J, Vandeput F, et al. Phosphodiesterase inhibition in heart failure. Heart Fail Rev 2009; 14: 255–63.

  125. 125.

    Batchelder K, Mayosi BM. Pentoxifylline for heart failure: a systematic review. S Afr Med J 2005; 95: 171–5.

  126. 126.

    Mistry NF, Cresci S. PPAR transcriptional activator complex polymorphisms and the promise of individualized therapy for heart failure. Heart Fail Rev 2010; 15: 197–207.

  127. 127.

    Massie BM, Carson PE, McMurray JJ, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008; 359: 2456–67.

  128. 128.

    Deswal A, Richardson P, Bozkurt B, et al. Randomized trial of aldosterone antagonism in diastolic heart failure (RAAM-DHF) [abstract]. J Cardiac Failure 2010; 16: S7.

  129. 129.

    Bergstrom A, Andersson B, Edner M, et al. Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function: results of the Swedish Doppler-echocardiographic study (SWEDIC). Eur J Heart Fail 2004; 6: 453–61.

  130. 130.

    Zhou J, Shi H, Zhang J, et al. Rationale and design of the beta-blocker in heart failure with normal left ventricular ejection fraction (beta-PRESERVE) study. Eur J Heart Fail 2010; 12: 181–5.

  131. 131.

    Levitan EB, Wolk A, Mittleman MA. Fish consumption, marine omega-3 fatty acids, and incidence of heart failure: a population-based prospective study of middle-aged and elderly men. Eur Heart J 2009; 30: 1495–500.

  132. 132.

    Dijkstra SC, Brouwer IA, van Rooij FJ, et al. Intake of very long chain n-3 fatty acids from fish and the incidence of heart failure: the Rotterdam Study. Eur J Heart Fail 2009; 11: 922–8.

  133. 133.

    Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372: 1223–30.

  134. 134.

    Jenkins DJ, Josse AR, Beyene J, et al. Fish-oil supplementation in patients with implantable cardioverter defibrillators: a meta-analysis. CMAJ 2008; 178: 157–64.

  135. 135.

    Martinez-Quintana E, Rodriguez-Gonzalez F, Torres-Fuentes E, et al. Effect of omega-3 acids on clinical evolution, plasma inflammatory biomarkers and B-type natriuretic peptide levels in patients with coronary heart disease [in Spanish]. Med Clin (Barc) 2011; 136: 574–7.

  136. 136.

    Zhao YT, Shao L, Teng LL, et al. Effects of n-3 polyunsaturated fatty acid therapy on plasma inflammatory markers and N-terminal pro-brain natriuretic peptide in elderly patients with chronic heart failure. J Int Med Res 2009; 37: 1831–41.

  137. 137.

    Mostofsky E, Levitan EB, Wolk A, et al. Chocolate intake and incidence of heart failure. Circ Heart Fail 2010; 3: 612–6.

  138. 138.

    Amabile CM, Spencer AP. Keeping your patient with heart failure safe: a review of potentially dangerous medications. Arch Intern Med 2004; 164: 709–20.

  139. 139.

    Kober L, Torp-Pedersen C, McMurray JJ, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 2008; 358: 2678–87.

  140. 140.

    Nishimura RA, Holmes DR. Hypertrophic obstructive cardiomyopathy. N Engl J Med 2004; 350: 1320–7.

  141. 141.

    Sherrid MV, Barac I, McKenna WJ, et al. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2005; 45: 1251–8.

  142. 142.

    Morrissey RP, Philip KJ, Schwarz ER. Reconciling Q waves and late gadolinium enhancement with no angiographic evidence of coronary disease: cardiac sarcoidosis presenting as decompensated heart failure. Cardiovasc J Afr 2010; 21: 158–63.

  143. 143.

    Morrissey RP, Philip KJ, Schwarz ER. Cardiac abnormalities in Anderson-Fabry disease and Fabry’s cardiomyopathy. Cardiovasc J Afr 2011; 22: 38–44.

  144. 144.

    May HT, Horne BD, Carlquist JF, et al. Depression after coronary artery disease is associated with heart failure. J Am Coll Cardiol 2009; 53: 1440–7.

  145. 145.

    Rutledge T, Reis VA, Linke SE, et al. Depression in heart failure: a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes. J Am Coll Cardiol 2006; 48: 1527–37.

  146. 146.

    Amy KF, Jeanette Pohorence F, Philip FB. Depressive symptoms and inflammation among heart failure patients. Am Heart J 2005; 150: 132–6.

  147. 147.

    Aguiar VB, Ochiai ME, Cardoso JN, et al. Relationship between depression, BNP levels and ventricular impairment in heart failure [in Spanish]. Arq Bras Cardiol 2010; 95: 732–7.

  148. 148.

    Shapiro PA. Treatment of depression in patients with congestive heart failure. Heart Fail Rev 2009; 14: 7–12.

  149. 149.

    Medina M, Walker C, Steinke EE, et al. Sexual concerns and sexual counseling in heart failure. Prog Cardiovasc Nurs 2009; 24: 141–8.

  150. 150.

    Mandras SA, Uber PA, Mehra MR. Sexual activity and chronic heart failure. Mayo Clin Proc 2007; 82: 1203–10.

  151. 151.

    Schwarz ER, Rastogi S, Kapur V, et al. Erectile dysfunction in heart failure patients. J Am Coll Cardiol 2006; 48: 1111–9.

  152. 152.

    Katz SD, Parker JD, Glasser DB, et al. Efficacy and safety of sildenafil citrate in men with erectile dysfunction and chronic heart failure. Am J Cardiol 2005; 95: 36–42.

  153. 153.

    Ritzema J, Troughton R, Melton I, et al. Physician-directed patient self-management of left atrial pressure in advanced chronic heart failure. Circulation 2010; 121: 1086–95.

  154. 154.

    Abraham WT, Adamson PB. Primary results of the CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients (CHAMPION) Trial. European Society of Cardiology Heart Failure Congress. Berlin: 2010 [online]. Available from URL: http://www.escardio.org/congresses/HF2010/slides-trials/Documents/HF2010-CHAMPION-Abraham.pdf [Accessed 2011 May 2].

Download references

Author information

Correspondence to Lawrence Czer MD.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Morrissey, R.P., Czer, L. & Shah, P.K. Chronic Heart Failure. Am J Cardiovasc Drugs 11, 153–171 (2011). https://doi.org/10.2165/11592090-000000000-00000

Download citation

Keywords

  • Chronic Heart Failure
  • Carvedilol
  • Valsartan
  • Candesartan
  • Aliskiren